tanshinone has been researched along with Chronic Illness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Y; Chen, L; Guo, QH; Guo, YJ; Ji, ES; Wang, N; Zhao, YS | 1 |
| Cheng, D; He, Z; Sun, C; Xu, Y | 1 |
2 other study(ies) available for tanshinone and Chronic Illness
| Article | Year |
|---|---|
Tanshinone IIA protects against chronic intermittent hypoxia-induced myocardial injury via activating the endothelin 1 pathway.
Topics: Abietanes; Animals; Apoptosis; Blood Pressure; Cardiotonic Agents; Chronic Disease; Electrocardiography; Endothelin-1; Heart Function Tests; Hemodynamics; Hypoxia; Male; Myocardium; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Synthase Type III; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Signal Transduction; Systole | 2017 |
Reduction of atrial fibrillation by Tanshinone IIA in chronic heart failure.
Topics: Abietanes; Acetylcholine; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; Chronic Disease; Disease Models, Animal; Echocardiography; Electrocardiography; Female; Heart Atria; Heart Failure; Heart Rate; Isolated Heart Preparation; Isoproterenol; Rabbits; Refractory Period, Electrophysiological; Time Factors | 2016 |